Asset Details
Do you wish to reserve the book?
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
Do you wish to request the book?
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women
2010
Overview
Patients who are diagnosed with osteoporosis and beginning treatment often discontinue their osteoporosis medication relatively early after the start of treatment because of their poor recognition of fracture risk and the asymptomatic nature of osteoporosis. In this study we aimed to assess adherence to treatment with 1 μg alfacalcidol (D), 60 mg raloxifene (R) or a combination of both (D + R) for 1 year in postmenopausal Japanese women with osteoporosis or osteopenia. We defined persistence of D and R as continuing to take tablets for more than 7 of any 14 days immediately before the 1-year visit. A total of 137 subjects aged 49-81 years [64.9 ± 7.0 years, 16.0 ± 12.7 years since menopause (YSM)] were randomly assigned to each treatment group. The proportions persisting with each treatment group at 1 year were 61.4, 65.3, 55.1% for D, R and D + R groups, respectively whereas the compliance to each therapy as judged by the medical possession ratio (MPR) at 1 year were 77.5, 93.8, 78.4%, respectively. There were no significant differences in persistence, compliance and the number of subjects who discontinued treatment due to adverse events among each group. We found significant inverse correlations in percent changes at 1 year between compliance and serum BAP in R and D + R groups or urinary (u-) CTX in the R group. The changes in the level of serum BAP and u-CTX were significantly higher in high-compliance patients (MPR > 80%) treated with raloxifene alone or concomitantly with alfacalcidol compared to those in low-compliance patients.
Publisher
Japan : Springer Japan,Springer Japan,Springer,Springer Nature B.V
Subject
/ Aged
/ Biological and medical sciences
/ Bone and Bones - drug effects
/ Bone Density Conservation Agents - adverse effects
/ Bone Density Conservation Agents - therapeutic use
/ Bone Diseases, Metabolic - blood
/ Bone Diseases, Metabolic - drug therapy
/ Bone Diseases, Metabolic - urine
/ Diseases of the osteoarticular system
/ Female
/ Humans
/ Hydroxycholecalciferols - adverse effects
/ Hydroxycholecalciferols - therapeutic use
/ Japan
/ Medication Adherence - statistics & numerical data
/ Medicine
/ Osteoporosis, Postmenopausal - blood
/ Osteoporosis, Postmenopausal - drug therapy
/ Osteoporosis, Postmenopausal - urine
/ Osteoporosis. Osteomalacia. Paget disease
/ Raloxifene Hydrochloride - adverse effects
/ Raloxifene Hydrochloride - therapeutic use
/ Women
